Skip to main content
SpringerLink
Log in

Drug-Induced Sleep Disturbances

Focus on Nonpsychotropic Medications

  • Review Article
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Different medications can have significant effects on sleep quality and/or quantity. When prescribing medications it is important to be aware of these possible adverse effects of drugs. Disturbances of the sleep/wake cycle caused by medications can vary and include insomnia, daytime sleepiness, nightmares and changes in the sleep architecture. Psychotropic drugs are well known to have an effect on the sleep/wake cycle, but there is only limited information about the sleep effects of nonpsychotropic medications. Cardiovascular drugs, especially β-blockers, which are widely used drugs, often change the sleep architecture and cause nightmares and insomnia. Both of these effects can be a potential source of noncompliance. Because of the complicated relationship between sleep, nocturnal asthma and antiasthmatic agents, the appropriate dosage and timing of medications should always be considered. Patients with Parkinson’s disease often experience disrupted sleep due to their disorder and the adverse effects of anti-parkinsonian medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Compendium of Pharmaceuticals and Specialties (CPS). 27th edition. Ottawa: Canadian Pharmaceutical Association, 1992

  2. Devins GM, Edworthy SM, Paul LC, et al. Restless sleep, illness intrusiveness, and depressive symptoms in three chronic illness conditions: rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Psychosom Res 1993; 37(2): 163–70

    PubMed  CAS  Google Scholar 

  3. Sloan EP, Shapiro CM, editors. Insomnia in the medically ill and behavioural treatment approaches to insomnia. J Psychosom Res 1993; 37 Suppl. 1: 19–38

    Google Scholar 

  4. Davies DM, editor. Textbook of adverse drug reactions. 4th edition. New York: Oxford Medical Publications, 1991

    Google Scholar 

  5. Shapiro CM, Flanigan MJ. Function of sleep. BMJ 1993; 306: 383–5

    PubMed  CAS  Google Scholar 

  6. Barinaga M. To sleep, perchance to…learn? New studies say yes. Science 1994 Jul 29; 265: 603–4

    PubMed  CAS  Google Scholar 

  7. Diagnostic Classification Steering Committee. International classification of sleep disorders: diagnostic and coding manual. Rochester, Minnesota: American Sleep Disorders Association, 1990

    Google Scholar 

  8. Broughton RJ, Shapiro CM. Parasomnias. In: Shapiro CM, editor. Sleep solutions series. St. Laurent, Quebec: Kommunicom Publications, 1993

    Google Scholar 

  9. Burgess M, Marks IM, Gill M. Postal self-exposure treatment of recurrent nightmares. Br J Psychiatry 1994; 165: 388–91

    PubMed  CAS  Google Scholar 

  10. Buysse DJ. Drugs affecting sleep, sleepiness and performance. In: Monk TH, editor. Sleep, sleepiness and performance. New York: John Wiley & Sons Ltd, 1991: 250–306

    Google Scholar 

  11. Nicholson AN, Bradley CM, Pascoe PA. Medications: effect on sleep and wakefulness. In: Kruger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: WB Saunders Co., 1994: 364–372

    Google Scholar 

  12. Robinson RW, Zwillich CW. The effect of drugs on breathing during sleep: symposium on sleep disorders. Clin Chest Med 1985 Dec; 6(4): 603–614

    PubMed  CAS  Google Scholar 

  13. Boutroy MJ. Drug-induced apnea. Biol Neonat 1994; 65: 252–7

    CAS  Google Scholar 

  14. Hamilton M, Shapiro CM. Depression. In: Peck DF, Shapiro CM, editors. Measuring human problems: a practical guide. Chichester: John Wiley and Sons Ltd., 1990: 49–72

    Google Scholar 

  15. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262(11): 1479–84

    PubMed  CAS  Google Scholar 

  16. Breslau N, Roth T, Roehrs TA, et al. Sleep disturbance and psychiatric disorders. Sleep Res 1995; 24: 205

    Google Scholar 

  17. Van Moffaert MMMP. Sleep disorders and depression: the ‘chicken and egg’ situation. J Psychosom Res 1994; 38 Suppl. 1: 9–13

    PubMed  Google Scholar 

  18. Idzikowski C. Insomnia and depression - sleep EEG changes. J Psychosom Res 1994; 38 Suppl. 1: 27–40

    PubMed  Google Scholar 

  19. Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, Captopril, enalapril and Propranolol. J Hum Hypertens 1990; 4: 217–25

    PubMed  CAS  Google Scholar 

  20. Hume A. Applying quality of life data in practice: considerations for antihypertensive therapy. J Fam Pract 1989; 28(4): 403–11

    PubMed  CAS  Google Scholar 

  21. Croog SH, Levine S, Testa MA. The effects of antihypertensive therapy on the quality oflife. N Engl J Med 1986; 314: 1657–64

    PubMed  CAS  Google Scholar 

  22. Monti JM. Disturbances of sleep and wakefulness associated with the use of antihypertensive agents. Life Sci 1987 Oct 26; 41(17): 1979–88

    PubMed  CAS  Google Scholar 

  23. Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982; 2(1): 14–39

    PubMed  CAS  Google Scholar 

  24. Idzikowski C, Shapiro CM. Non-psychotropic drugs and sleep. In: Shapiro CM, editor. ABC of sleep disorders. London: BMJ Publishing Group, 1993: 70–74

    Google Scholar 

  25. Swales JD. ACE Inhibitors and the quality of life. J Cardiovasc Pharmacol 1987; 9 Suppl.: S22–S25

    PubMed  Google Scholar 

  26. Materson BJ, Preston RA. Angiotensin-Converting enzyme inhibitors in hypertension - a dozen years of experience. Arch Intern Med 1994; 154: 513–23

    PubMed  CAS  Google Scholar 

  27. Breckenridge A. Angiotensin converting enzyme inhibitors and quality of life. Am J Hypertens 1991; 4: 79S–82S

    PubMed  CAS  Google Scholar 

  28. Herlitz H. ACE-inhibitors and quality of life. Scand J Prim Care 1990; Suppl 1: 85–8

    CAS  Google Scholar 

  29. Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: a randomized double-blind controlled trial of Captopril and atenolol. J Hypertens 1990; 8: 463–466

    PubMed  CAS  Google Scholar 

  30. Prichard BNC. Risk-benefits of antihypertensive drugs — betablockers. Clin Exp Pharmacol Physiol 1988; 15: 203–13

    PubMed  CAS  Google Scholar 

  31. Bengtsson C, Lennartsson J, Lindquist O, et al. Sleep disturbances, nightmares and other possible central nervous disturbances in a population sample of women, with special reference to those on antihypertensive drugs. Eur J Clin Pharmacol 1980; 17: 173–7

    PubMed  CAS  Google Scholar 

  32. McAinish J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990; 46: 163–97

    Google Scholar 

  33. Ongini E, Milani S, Marzanatti M, et al. Effects of selected beta-adrenergic blocking agents on sleep stages in spontaneously hypertensive rats. J Pharmacol Exp Ther 1991; 257(1): 114–9

    PubMed  CAS  Google Scholar 

  34. Silberfarb PM, Oxman TE. The effects of cancer therapies on the central nervous system. Adv Psychosom Med 1988; 18: 13–25

    PubMed  CAS  Google Scholar 

  35. Silberfarb PM, Hauri PM, Oxman TE, et al. Assessment of sleep in patients with lung cancer and breast cancer. J Clin Oncol 1993; 11(5): 997–1004

    PubMed  CAS  Google Scholar 

  36. Silberfarb PM, Hauri PJ, Oxman TE, et al. Insomnia in cancer patients. Soc Sci Med 1985; 20(8): 849–50

    PubMed  CAS  Google Scholar 

  37. Da-Shih Hu, Silberfarb PM. Management of sleep problems in cancer patients. Oncology 1991; 5(9): 23–7

    Google Scholar 

  38. Kraft M, Martin RJ. Chronobiology and chronotherapy in medicine. Disease-a-Month 1995 Aug; 41(8): 501–75

    Google Scholar 

  39. Hrushensky WJM, Bjarnason GA. Circadian cancer therapy. J Clin Oncol 1993; 11: 1403–17

    Google Scholar 

  40. Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7: 401–20

    PubMed  CAS  Google Scholar 

  41. Lemmer B, editor. Chronopharmacology. Marcel Dekker: New York, 1989

    Google Scholar 

  42. Drigan R, Spirito A, Gelber RD. Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1992; 20: 13–21

    PubMed  CAS  Google Scholar 

  43. Moldofsky H. Central nervous system and peripheral immune functions and the sleep-wake system. J Psychiatr Neurosci 1994; 19(5): 368–74

    CAS  Google Scholar 

  44. Krueger M, Toth LA, Obal F, et al. Infections, cytokines and sleep. In: Smirne S, Franceschi M, Ferini-Strambi L, editors. Sleep, hormones and immunological system. Milano: Masson, 1992

    Google Scholar 

  45. Smolensky MH, Barnes PJ, Reinberg A, et al. Chronobiology and asthma I: day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. J Asthma 1986; 23(6): 321–43

    PubMed  CAS  Google Scholar 

  46. Smolensky MH, McGovern JP, Scott PH et al. Chronobiology and asthma II: body-time dependent differences in the kinetics and effects of bronchodilator medications. J Asthma 1987; 24(2): 91–134

    PubMed  CAS  Google Scholar 

  47. Reinberg A, Smolensky MH, D’Alonzo GE, et al. Chronobiology and asthma III: timing corticotherapy to biological rhythms to optimize treatment goals. J Asthma 1988; 25(4) 219–48

    PubMed  CAS  Google Scholar 

  48. D’Alonzon GE, Smolensky M. The chronopharmacological application of theophylline therapy in asthma. Monaldi Arch Chest Dis 1994 Feb; 49(1): 36–43

    Google Scholar 

  49. Kales A, Beali GN, Bajor GF, et al. Sleep studies in asthmatic adults: relationship of attacks to sleep stage and time of night. JAllergol 1968; 41: 164–73

    CAS  Google Scholar 

  50. Montplaisir J, Walsh J, Malo JL. Nocturnal asthma: features of attacks, sleep and breathing patterns. Am Rev Respir Dis 1982; 125: 18–22

    PubMed  CAS  Google Scholar 

  51. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1991; 4: 540–6

    Google Scholar 

  52. Gislason T, Almqvist M. Somatic diseases and sleep complaints. Acta Med Scand 1987; 221: 475–81

    PubMed  CAS  Google Scholar 

  53. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med 1988; 85 (Suppl. 1B): 6–8

    PubMed  CAS  Google Scholar 

  54. Connoly CK. Diurnal rhythms in airway obstruction. Br J Dis Chest 1979; 73: 357–66

    Google Scholar 

  55. Janson C, Gislason T, Boman G, et al. Sleep disturbances in patients with asthma. Resp Med 1990; 84: 37–42

    CAS  Google Scholar 

  56. Clark TJH, Hetzel MR. Diurnal variation of asthma. Br J Dis Chest 1977; 71: 87–92

    PubMed  CAS  Google Scholar 

  57. Douglas NJ. Asthma. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia: WB. Saunders Co., 1994: 748–57

    Google Scholar 

  58. Martin JR, Cicutto LC, Ballard RD. Factors related to the nocturnal worsening of asthma. Am Rev Respir Dis 1990; 141: 33–8

    PubMed  CAS  Google Scholar 

  59. Martin RJ. The sleep-related worsening of lower airways obstruction: understanding and intervention. Med Clin North Am 1990 May; 74(3): 701–14

    PubMed  CAS  Google Scholar 

  60. Martin RJ. Nocturnal asthma: circadian rhythms and therapeutic interventions. Am Rev Res Dis 1993 Jun; 147 (6 Pt 2): S25–8

    CAS  Google Scholar 

  61. Catterall JR, Rhind GB, Stewart IC, et al. Effect of sleep deprivation on overnight bronchoconstriction in nocturnal asthma. Thorax 1986; 41: 676–80

    PubMed  CAS  Google Scholar 

  62. Shapiro CM, Catterall JR, Montgomery I. Do asthmatics suffer from bronchoconstriction during rapid eye movement sleep? BMJ 1986; 292: 1161–5

    PubMed  CAS  Google Scholar 

  63. Barnes PJ. New drugs for asthma. Eur Respir J 1992; 5: 1126–36

    PubMed  CAS  Google Scholar 

  64. Rhind GB, Connaughton JJ, McFie J, et al. Sustained release choline theophyllinate in nocturnal asthma. BMJ 1985; 291: 1605–7

    PubMed  CAS  Google Scholar 

  65. Janson C, Gislason T, Almqvist M, et al. Theophylline disturbs sleep mainly in caffeine-sensitive persons. Pulm Pharmacol 1989; 2: 125–9

    PubMed  CAS  Google Scholar 

  66. Janson C, Gislason T, Laxmyr L, et al. Sleep disturbances in asthma: theophylline versus enprofylline. Ups J Med Sci 1991; 96: 119–27

    PubMed  CAS  Google Scholar 

  67. Fitzpatrick MF, Engleman HM, Boellert F, et al. Effect of therapeutic theophylline levels on the sleep quality and daytime cognitive performance of normal subjects. Am Rev Resp Dis 1992; 145: 1355–8

    PubMed  CAS  Google Scholar 

  68. Fitzpatrick MF, Engelman H, Whyte KF, et al. Morbidity in nocturnal asthma: sleep quality and daytime cognitive performance. Thorax 1991; 46: 569–73

    PubMed  CAS  Google Scholar 

  69. Kaplan J, Frederickson PA, Renaux SA, et al. Theophylline effect on sleep in normal subjects. Chest 1993; 103(1): 193–5

    PubMed  CAS  Google Scholar 

  70. Youngchaiyud P, Permikul C, Suthamsmai T, et al. A doubleblind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma. Allergy 1995 Jan; 50(1): 28–33

    PubMed  CAS  Google Scholar 

  71. Avital A, Steljes DG, Pasterkamp H, et al. Sleep quality in children with asthma treated with theophylline or chromolyn sodium. J Pediatr 1991; 119(6): 979–84

    PubMed  CAS  Google Scholar 

  72. Fitzpatrick MF, Mackay T, Driver H, et al. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta-2 agonist. BMJ 1990; 301: 1365–8

    PubMed  CAS  Google Scholar 

  73. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutical potential in reversible obstructive airways disease. Allergol Immunopathol (Madr) 1992 Mar-Apr; 20(2): 72–84

    CAS  Google Scholar 

  74. Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, crossover comparison of salmeterol and salbutamol in pateints with asthma. Am J Respir Crit Care Med 1996 Aug; 154 (2 pt 1): 324–8

    PubMed  CAS  Google Scholar 

  75. Nausieda PA. Sleep disorders. In: Koller WC, editor. Handbook of Parkinsons disease. New York: Marcel Dekker Inc., 1987: 371–380

    Google Scholar 

  76. van Hilten JJ, Weggeman M, van der Velde, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinsons disease. J Neural Transm (P-D Sect) 1993; 5: 235–44

    Google Scholar 

  77. Nausieda PA, Weiner WJ, Kaplan LR, et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183–94

    PubMed  CAS  Google Scholar 

  78. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinsons disease. Clin Neuropharmacol 1988; 6: 512–9

    Google Scholar 

  79. Parkes D. Sleep and Parkinsons disease. In: Quinn NP, Jenner PG, editors. Disorders of movement: clinical pharmacological and physiological aspects. London: Academic Press, 1989: 125–135

    Google Scholar 

  80. Askenasy JJM. Sleep in Parkinsons disease. Acta Neurol Scand 1993; 87: 167–70

    PubMed  CAS  Google Scholar 

  81. Askenasy JJM. Sleep patterns in extrapyramidal disorders. Int J Neurol 1981; 15: 62–76

    PubMed  CAS  Google Scholar 

  82. Mouret J. Differences in sleep in patients with Parkinsons disease. Electroencephalogr Clin Neurophysiol 1975; 38: 653–7

    PubMed  CAS  Google Scholar 

  83. Groetz GC, Wilson RS, Tanner CM, et al. Relationship among pain, depression, and sleep alterations in Parkinsons disease. In: MD Yahr, KJ Bergmann, editors. Advances in neurology, vol. 45. New York: Raven Press, 1986 346–7

    Google Scholar 

  84. Apps MCP, Sheaff PC, Ingram DA, et al. Respiration and sleep in Parkinsons disease. J Neurol Neurosurg Psychiatry 1995; 48: 1240–5

    Google Scholar 

  85. Klawans HL, Tanner C, McDermott J. Myoclonus and Parkinsonism. Clin Neuropharmacol 1986; 9(2): 202–5

    PubMed  CAS  Google Scholar 

  86. Shapiro CM, Driver H. Stress and sleep. Sleep and its implications for the military. In: Roussel B, Jouvet M, editors. Proceedings of the 27th DRG Seminar; 1988 Lyon, France, Laboratoire de Medecine Experimentale, Universite Claude Bernard, ACEML NATO Colloquium. Lyon: Plenum Press, 1988: 133–46

    Google Scholar 

  87. Sandor P, Shapiro CM. Sleep patterns in depression and anxiety: theory and pharmacological effects. J Psychosom Res 1994; 38 Suppl. 1: 125–39

    PubMed  Google Scholar 

  88. Starkstein SE, Preziosi TJ, Robinson RG. Sleep disorders, pain, and depression in Parkinsons disease. Eur Neurol 1991; 31: 352–5

    PubMed  CAS  Google Scholar 

  89. Kostic VS, Susic V, Przedborski S. Sleep EEG in depressed and nondepressed patients with Parkinsons disease. J Neuropsychiatry Clin Neurosci 1991; 3: 176–9

    PubMed  CAS  Google Scholar 

  90. Factor SA, McAlarney T, Weiner WJ, et al. Sleep disorders and sleep effect in Parkinsons disease. Mov Disord 1990; 5(4): 280–5

    PubMed  CAS  Google Scholar 

  91. Bergonzoni P, Chiurulla C, Gambi D, et al. L-dopa plus dopadecarboxilase inhibitor: sleep organisation in Parkinsons syndrome before and after treatment. Acta Neurol Belg 1975; 75: 5–10

    Google Scholar 

  92. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669–75

    PubMed  CAS  Google Scholar 

  93. Sharf B, Moskovitz C, Lupton MD, et al. Dream phenomenon induced by chronic levodopa therapy. J Neural Transm 1978; 43: 143–51

    PubMed  CAS  Google Scholar 

  94. Nausieda PA, Glantz R, Weber S, et al. Psychiatric complications of levodopa therapy of Parkinsons disease. Adv Neurol 1984; 40: 271–7

    PubMed  CAS  Google Scholar 

  95. Kales A, Ansel RD, Markham CH, et al. Sleep in patients with Parkinsons disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther 1971; 12: 397–407

    PubMed  CAS  Google Scholar 

  96. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970; II: 177–80

    Google Scholar 

  97. Van den Kerchove M, Jacquy J, Gonce M, et al. Sustained-release levodopa in Parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 1993; 93: 32–9

    PubMed  Google Scholar 

  98. Cummings JL. Neuropsychiatric complications of drug treatment of Parkinson’s disease. In: Huber SJ, Cummings LJ, editors. Parkinsons disease: neurobehavioural aspects. New York: Oxford University Press, 1992: 313–27

    Google Scholar 

  99. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinsons disease. Neurology 1993; 43 Suppl. 6: S47–S52

    PubMed  CAS  Google Scholar 

  100. Koller WC. Controlled-release carbidopa-levodopa: old drugnew drug. Neurology 1992; 42 Suppl. 1: 4–5

    PubMed  CAS  Google Scholar 

  101. Schmidt HS, Knopp W Sleep in Parkinsons disease: the effect of L-dopa. Psychophysiology 1972; 9: 88

    Google Scholar 

  102. Wyatt RJ, Chase TN, Scott J, et al. Effect of L-dopa on the sleep of man. Nature 1970; 228: 999–1001

    PubMed  CAS  Google Scholar 

  103. Bergonzi P, Chiurulla C, Cianchetti C, et al. Clinical pharmacology as an approach to the study of biochemical sleep mechanisms; the action of L-dopa. Confirm Neurol 1974; 36: 5–22

    CAS  Google Scholar 

  104. Fram DH, Murphy DL, Goodwin FK, et al. L-dopa and sleep in depressed patients. Psychophysiology 1970; 7: 316–7

    Google Scholar 

  105. Puca FM, Bricolo A, Turella G. Effect of L-dopa or amantadine therapy on sleep spindles in parkinsonism. Electroencephalogr Clin Neurophysiol 1973; 35: 327–30

    PubMed  CAS  Google Scholar 

  106. Greenberg R, Pearlman CA. L-dopa parkinsonism and sleep. Psychophysiology 1972; 7: 314–5

    Google Scholar 

  107. Pfeiffer R. Optimization of levodopa therapy. Neurology 1992; 42 Suppl. 1: 39–43

    PubMed  CAS  Google Scholar 

  108. Askenasy JJM, Yahr MD. Reversal of sleep disturbance in Parkinsons disease by antiparkinson therapy. Neurology 1985; 35: 527–32

    PubMed  CAS  Google Scholar 

  109. Klawans HL, Goetz C, Bergen D. Levodopa-induced myoclonus. Arch Neurol 1975 May; 32: 331–4

    Google Scholar 

  110. Lavie P, Bental E, Goshen H, et al. REM ocular activity in Parkinsonian patients chronically treated with levodopa. J Neural Transm 1980; 47(1): 61–7

    PubMed  CAS  Google Scholar 

  111. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders. Arch Gen Psychiatry 1992; 49: 651–68

    PubMed  CAS  Google Scholar 

  112. Prinz PN, Vitiello MV. Sleep in Alzheimers disease. In: Morley JE, Roth T, editors. Sleep disorders and insomnia in the elderly. Facts Res Gerontol 1993; 2 Suppl.: 55–68

    Google Scholar 

  113. Mindham RHS, Ahmed SWA, Clough CG. A controlled study of dementia in Parkinsons disease. J Neurol Neurosurg Psychiatry 1982; 45: 969–74

    PubMed  CAS  Google Scholar 

  114. Golbe L. Deprenyl as symptomatic therapy in Parkinsons disease. Clin Neuropharmacol 1988; 11: 387–400

    PubMed  CAS  Google Scholar 

  115. Eldepryl Product Monograph. Toronto, Ontario, Canada: Deprenyl Research Ltd., 1989 Dec 22

  116. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (()-deprenyl. Arch Gen Psychiatry 1989; 46: 45–50

    PubMed  CAS  Google Scholar 

  117. Stern GM, Lees AJ, Sandler M. Recent observations on the clinical pharmacology of deprenyl. J Neural Trans 1978; 43: 245–51

    CAS  Google Scholar 

  118. Lavie P, Wajsbort J, Youdim MBH. Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 1980; 4: 303–7

    PubMed  CAS  Google Scholar 

  119. Reinish LW, MacFarlane JG, Sandor P, et al. REM changes in narcolepsy with Selegiline. Sleep 1995; 18(5): 362–7

    PubMed  CAS  Google Scholar 

  120. Schwab RS, Poskanzer DC, England AC, et al. Amantadine in Parkinsons disease: review of more than two years experience. JAMA 1972; 222(7): 792–5

    PubMed  CAS  Google Scholar 

  121. Timberlake WH, Vance MA. Four-year treatment of patients with Parkinsonism using amantadine alone or with levodopa. Ann Neurol 1978; 3: 119–28

    PubMed  CAS  Google Scholar 

  122. Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 2nd ed. Philadelphia: W.B. Saunders Company, 1994

    Google Scholar 

  123. Kay DC, Samiuddin Z. Sleep disorders associated with drug abuse and drugs of abuse. In: Williams RL, Karacan I, Moore CA, editors. Sleep disorders: diagnosis and treatment. New York: John Wiley & Sons, 1988: 315–71

    Google Scholar 

  124. Ashton H. The effect of drugs on sleep. In: Cooper R, editor. Sleep. London: Chapman and Hall Medical, 1994: 175–211

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Behavioural Sciences, Semmelweis Medical University, Budapest, Hungary

    Marta Novak

  2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    Marta Novak &  Colin M. Shapiro

Authors
  1. Marta Novak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin M. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novak, M., Shapiro, C.M. Drug-Induced Sleep Disturbances. Drug-Safety 16, 133–149 (1997). https://doi.org/10.2165/00002018-199716020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199716020-00005

Keywords

Search

Navigation